Prevent identity attacks and secure access to apps and resources. Prevent identity attacks and secure access to applications and resources with strong authentication and risk-based conditional access ...
Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) The systematic review included 35 publications on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback